Symbols

IMDX

Insight Molecular·NASDAQ

--(--)

IMDX fundamentals

IMDX Q4 2025 Earnings

Insight Molecular (IMDX) released its earnings on Mar 26, 2026: revenue was 1.14M (YoY -23.35%), beat estimates; EPS was -0.27 (YoY +86.01%), missed estimates.

Revenue / YoY

1.14M

-23.35%

EPS / YoY

-0.27

+86.01%

Report date

Mar 26, 2026

IMDX Earnings Call Summary for Q4,2025

FDA Submission Success: First DDC FDNA assay submitted to FDA, signaling regulatory progress.
Registry Growth: 28/50 centers engaged in GALACTIC registry, driving clinical validation and in-house adoption.
Head-to-Head Validation: 140+ patient study shows equivalence to reference lab, leading to in-house testing.
Heart Transplant Expansion: Targeting $2B+ market with CMS reimbursement and FDA 510(k) submissions.
Financial Discipline: $26M funding supports $7.5M quarterly burn, with H2 revenue offsetting costs.
Market Potential: Screening reimbursement expansion and anti-CD38 drug adoption boost testing demand.

Earnings

EPS

Revenue

Revenue & Expenses

IMDX has released its 2025 Q4 earnings report, with revenue of 1.14M, reflecting a YoY change of -23.35%, and net profit of -22.95M, showing a YoY change of 31.50%. The Sankey diagram below clearly presents IMDX's revenue sources and cost distribution.

Key Indicators

Insight Molecular (IMDX) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Insight Molecular (IMDX)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Insight Molecular (IMDX)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Insight Molecular (IMDX)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown